Navigation Links
Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
Date:2/15/2008

NEW YORK, Feb. 15 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (ITI), announced the presentation of preclinical data on ITI-007, its first-in-class dual 5HT2A receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM) for the treatment of schizophrenia, and ITI-002, ITI's family of compounds that inhibit a novel intracellular target for the treatment of cognitive dysfunction in schizophrenia. Data characterizing the pharmacological profile of these drug candidates were highlighted in an oral presentation given last week at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders. ITI-007 is currently in Phase I clinical trials for the treatment of schizophrenia.

"We believe the novel pharmacological properties of ITI-007 may provide new treatment alternatives with significant safety and patient compliance-related advantages over currently available therapies for the treatment of schizophrenia," said Sharon Mates, Ph.D., Chairman and Chief Executive Officer of Intra-Cellular Therapies. "In addition, we are developing ITI-002 to treat cognitive dysfunction in schizophrenia which remains an important quality of life issue for individuals with schizophrenia and is not addressed by current medications."

ITI-007 Study Results

In vitro, ITI-007 was shown to be a potent, sub-nanomolar, antagonist at 5HT2A receptors with a 60-fold higher affinity for 5HT2A receptors over D2 receptors. In vivo, ITI-007 produced an intracellular protein phosphorylation pattern consistent with the activity of a partial agonist at pre-synaptic D2 receptors. This pre-synaptic partial agonist activity preserves normal dopamine metabolism rather than causing a dramatic increase as seen with other antipsychotic therapies. Behaviorally, ITI-007 inhibited serotonin induced head twitches. Additionally, ITI-007 was shown to have an affinity for the serotonin reuptake site, an activity that potentially may be beneficial in treating affective disord
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
2. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
3. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
4. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
5. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
8. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
9. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... According to market research ... Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical ... & Geography - Global Trends & Forecast to ... lyophilization market on the basis of various types, ... the market size of each of these segments ...
(Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014 ... continues to grow, with the publication of two papers ... Otolaryngology – Head and Neck Surgery ... of both objective and subjective measures of sleep disordered ... therapy for the reduction in obstructive sleep apnea severity ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. ... Inc. (PGDx), a provider of advanced cancer ... Medicines , a leader in discovering and developing ... today disclosed the first-ever comprehensive genomic study of ... deadly cancer of the female reproductive system, also ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... Colo. , June 1 Encision Inc. (OTC ... technology that is emerging as a standard of care in ... purchasing agreement with HealthTrust Purchasing Group, LP ("HealthTrust"), effective ... are "Laparoscopic Safety Instruments – Active Electrode Monitoring Laparoscopy". , ...
... DURECT Corporation (Nasdaq: DRRX ) announced today that James E. Brown , ... Conference on Thursday, June 10 at 10:30 a.m. Eastern Time . ... .   , , , ... , , ...
Cached Medicine Technology:Encision and HealthTrust Purchasing Group Sign Purchasing Agreement 2DURECT to Present at the Jefferies Global Life Sciences Conference 2
(Date:9/21/2014)... Huntington, New York (PRWEB) September 21, 2014 ... release of their Risk Management Portal designed for ... applications with the intent to support effective risk ... is scheduled to go live coinciding with Waldorf’s ... September 21-24, 2014. , These applications were developed ...
(Date:9/21/2014)... September 21, 2014 "I wanted to ... having to consume sugary, foul-tasting energy drinks," said an ... always just want to drink plain, old coffee. That ... booster." , He developed ENERG CHEWING GUM to provide ... weight loss. The formula contains nutritious vitamins, minerals and ...
(Date:9/21/2014)... of Sparta. , Ancient Greek warriors were fed a ... of battle on distant fields. Cancer cells that metastasize ... study revealing previously unknown differences between cancer cells that ... those that travel to other organs. , Given that ... primary cause of cancer-related death, understanding how they successfully ...
(Date:9/21/2014)... 21, 2014 "I want to help ... back but haven’t the money for chiropractors," said an ... have such a product for myself." , The Stretch ... stretch the thigh muscles and align the spine properly. ... relieves discomfort of pinched nerves. Compact and easy to ...
(Date:9/21/2014)... September 21, 2014 The Electronic ... and supports electronic medical records (EMR) and electronic ... federal healthcare legislation during the past five years ... during the five years to 2019. The 2009 ... Act established Medicare and Medicaid incentives to encourage ...
Breaking Medicine News(10 mins):Health News:Waldorf Risk Solutions Releases New Risk Management Portal 2Health News:Cancer cells adapt energy needs to spread illness to other organs 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4
... consumption of ground beef or processed meat is positively associated ... 23 in the online journal PLoS ONE . ... University of California, San Francisco, also found that the correlation ... barbequed, especially when well done. They suggest that ...
... WEDNESDAY, Nov. 23 (HealthDay News) -- Tall or short, it,s ... person,s height. Now, scientists have found that short people actually ... them significantly smaller than average. Studying DNA from more ... learned that those of short stature -- defined roughly as ...
... Science Foundation (ESF) has awarded this year,s European Latsis ... Planck Institute for Demographic Research in Rostock, Germany. The ... was awarded the prize for his contributions to research ... demographic research. The Prize was awarded on the eve ...
... News) -- U.S. high school students still aren,t eating enough ... Centers for Disease Control and Prevention researchers. The investigators ... 12 who took part in the National Youth Physical Activity ... 1.2 times per day for both fruits and vegetables. ...
... variations in the numbers indicate that improvements are possible," says ... a study in Boston, USA, 234 million major surgical procedures ... of 25 human beings undergoes a major surgical procedure each ... also risky. According to the WHO, serious complications occur in ...
... 23 (HealthDay News) -- Huge meals and unhealthy foods, heavy ... and stroke over the holidays, an expert warns. For ... grams of fat, according to the American Council on Exercise. ... health consequences," Dr. Niten Singh, a member of the Society ...
Cached Medicine News:Health News:Gene Shortage Might Lead to Shorter Height, Study Says 2Health News:ESF awards 13th European Latsis Prize to James Vaupel on pioneering demographic research 2Health News:U.S. Teens Don't Eat Enough Fruits and Veggies: CDC 2Health News:Creating safer surgery to save more lives 2Health News:Creating safer surgery to save more lives 3
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The APR Hip System offers a complete line of stems to precisely match patients' anatomic needs and address surgeon preferences....
Dual offset femoral stems, hip stems that provide unique and competitive features....
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
Medicine Products: